Evaluating Rifampin Use in Treating Prosthetic Valve Endocarditis Caused by Staphylococcus Aureus A Phase 3 Randomized Study Comparing Treatment With and Without Rifampin

What this Trial Is About

Researchers are evaluating treatment options for patients with probable or definite prosthetic valve endocarditis caused by Staphylococcus aureus. The study aims to determine whether not giving rifampin, an antibiotic, is no worse than giving rifampin alongside standard care. This is a Phase 3 randomized clinical trial led by Todd C. Lee MD MPH FIDSA. Participants will be randomly assigned to one of two groups one will receive adjunctive rifampin at a dose of 900 mg per day divided into 2-3 doses, while the other group will not receive rifampin. The study will follow participants for outcomes related to treatment success or failure, including monitoring for adverse reactions and other complications. During the trial, participants will be monitored for treatment failure over 180 days, including deaths, unplanned cardiac surgery, new embolic events, and relapse of bacteremia. Additional assessments within 56 days will track discontinuation of rifampin due to drug interactions or adverse reactions. Participants will be followed closely to evaluate safety and effectiveness throughout the study period, which extends up to 180 days after treatment begins.

Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus